Most Popular Stories
- Debt payments still mire HCA
- Forum: IT won't help much until practices shift operations
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
- Fitch changes not-for-profit hospital outlook to negative
- Rapid-response teams have little effect on cardiac arrest deaths
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
- A new strategy for harried physicians: See patients in groups
Poll
Featured Jobs
-
Florida Family Practitioner
StaffPointe, LLC - west , FL -
Colorado Family Practice
StaffPointe, LLC - southeast , CO -
Tennessee Neurologist
StaffPointe, LLC - near Chattanooga , TN -
Virginia Dialysis Registered Nurse
StaffPointe, LLC - north , VA -
Texas Dir. of Med/Surg
StaffPointe, LLC - east , TX
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
SPOTLIGHT: Revised study still finds that FDA approval rush may cause harm
July 3, 2008 — 1:26am ET | By Anne Zieger
Harvard University professor Daniel Carpenter has come out with a revised version of a study concluding that drugs moving too quickly through the FDA approval process are more likely to be linked to safety problems later. Though admitting to data mistakes in his original study, he stands behind his original conclusion, Carpenter says. According to his new numbers, between 1993 and 2005, 88 drugs approved near agency deadlines had a 15 percent chance of being identified as having severe safety problems, as compared with 5 percent of 226 other drugs. Article
Be the first to comment
Related Stories
- Avandia gets black-box warning
- ALSO NOTED: Health IT not likely to shift much in '08; HHS recommends better health data privacy protections; and much more...
- FDA rules on off-label article distribution issued
- SPOTLIGHT: FDA plans to issue more early warnings
- GAO to study FDA's post-approval review process
- SPOTLIGHT: Study: Last-minute drug approvals less safe
- ALSO NOTED: FDA investigates Roche, Novartis transplant drugs; Maryland hospital fined for radiation errors; and much more...
- SPOTLIGHT: FDA can't manage foreign drugmaker inspections
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- ALSO NOTED: Salmonella on Discovery shuttle is first step in biotech space program; After initial shock, providers adjusting to
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





